VerAvanti-At-A-Glance

Sep 22, 2026

Upload by Dipper

VerAvanti at a glance presents confidential business-plan style statements and a clinical value case for intravascular imaging. It frames growth in the neurovascular devices market alongside rising ischemic stroke incidence and the limitations of current imaging technologies. The document proposes real-time visualization using a laser angioscope with a MEMS actuator to improve visualization of vulnerable endothelial features and calcified plaques, then outlines market opportunity, scanning fiber endoscope advantages, leadership, and treatment challenges including stroke and CTO guidance gaps.

LanguageEnglish

CategoryPresentations

FormatPDF

Pages18

Reading Time6 min

AccessFree to download

Forward-looking Statements

Clinical Need:

Current Imaging technologylimits doctors'effectiveness

Solution:

Real-time visualization forbetter outcomes

What is theMarket Opportunity?

VerAvanti's

Scanning Fiber EndoscopeAdvantages

Leadership Members

Challenges of Current Treatment Options:

Stroke

VerAvanti Your Intravascular Eyes # Forward-looking Statements VerAvanti Inc.has not authorized any person to give any information nor to make any representations other than those contained in this 2024 Confidential BusinessPlan (this "Business Plan"),and,if given or made,you must not rely on such information and representations.This Business Plan does not constitute an offer to sellor a solicitation of an offer to buy securities in any jurisdiction where such an offer or solicitation is not authorized,or in which the person making such offer orsolicitation is not qualified to do so,or to any person other than the recipient to whom we delivered this Business Plan,or to any person to whom it is unlawful tomake such an offer.Certain information contained in this Business Plan may change after the date of this Business Plan,and delivery of this Business Plan does notimply that the information herein is correct as of any time subsequent to the date of the Business Plan. This Business Plan is confidential.The receipt of the Business Plan constitutes an agreement on the part of the recipient hereof:(1)that the information containedin this Business plan,as well as any supplemental information provided to the recipient by us or our representatives,either orally or in writing,is proprietary to us;(2)that the recipient shall maintain the confidentiality of the infomation contained in this Business Plan and any supplemental information;(3)that the recipient shall notreproduce,post,forward,or dstribute this Business Plan or any supplemental information,in whole or in part,except to the recipient's legal and financial advisors forthe purpose of evaluating a potential investment in VerAvanti;(4)that the recipient shall not use the information in this Business Plan or the supplemental informationfor any purpose other than to evaluate an investment in VerAvanti;and (5)that the recipient shall promptly return to us and/or destroy all copies of this Business Planand any supplemental infomation upon request.The agreements of the recipient set forth in the preceding sentence are intended for our benefit and we mayenforce such agreements. Certain of the matters discussed in this report about our and our subsidiaries'future performance,including,without limitation,future revenues,earnings,strategies,prospects,consequences and all other statements that are not purely historical constitute “forward-looking statements”within the meaning of the Private SecuritiesLitigation Reform Act of 1995.Such forward-looking statements are subject to risks and uncertainties,which could cause actual results to differ materially from thoseanticipated.Such statements are based on management's beliefs as well as assumptions made by and information currently available to management. # Clinical Need: ## Current Imaging technologylimits doctors'effectiveness The neurovascular devices market is forecasted to grow a robust CAGR of 8.7%,reaching $5.5 billion by 2028. In 2022,7.6 million new ischemic stroke cases were registered worldwide. 20.5 million people are living with heart disease Chronic Total Occlusion(CTO)occur in 1 of 5 patients having a cardiaccatheterization Most expert practitioners are successful in only 55%of these difficult cases,and only 10%of these cases are attempted 00 Solution: # Real-time visualization forbetter outcomes New endoscopic technology based on a MicroelectromechanicalSystem(MEMS)actuator scanning a laser at its tip A laser angioscope capable to see inside arteries in real time,fullcolor and forward Only imaging technology that can identify vulnerable endothelialfeatures,and identification of calcified plaques # What is theMarket Opportunity? The neurovascular device market is forecasted to grow a robustCAGR or 8.7%reaching $5.5 billion by 2028 10,000 interventional cardiologists in the USA performing about 7.1million interventions per year In 2022,7.6 million new ischemic stroke cases were registered

FAQs

What clinical problem does the document highlight?

It describes that current imaging technology limits doctors' effectiveness, failing to see forward and struggling to identify vulnerable endothelial features and complex atherosclerotic plaques.

What solution is proposed to improve outcomes?

It proposes real-time visualization using a laser angioscope driven by a Microelectromechanical System (MEMS) actuator scanning a laser at the tip, enabling full-color forward intravascular visualization.

What market opportunity does the document cite?

It forecasts robust neurovascular device market growth and provides procedure-volume context, including millions of annual angiography/arteriography procedures and high intervention volumes by interventional cardiologists.

Sep 22, 2026

Upload by Dipper